title: [The prolonged-action form of Lomir (isradipine) in the treatment of mild and moderate essential hypertension].
abstract: 24-hour monitoring of arterial pressure has been performed outpatiently in 20 subjects with mild or moderate essential hypertension using portable system Space Labs 90207. The design of the study implied 2 weeks of observation without any treatment followed by a 4-week course of lomir SRO-5 plus a 2-week course of lomir administration in a double dose. Control examination was performed at the end of each period. It was established that a 4-week lomir course results in a lowering of systolic and diastolic pressure by 8.4 + -2.1 and 6.9 + -1.3 mm Hg, respectively. Double-dose lomir was also effective: a fall in both systolic and diastolic pressure by 15.6 + -3.2 and 8.1 + -1.8 mm Hg, respectively, was achieved.
authors.forename: V V
authors.initials: VV
authors.lastname: Dmitriev
authors.forename: G G
authors.initials: GG
authors.lastname: Arabidze
authors.forename: O N
authors.initials: ON
authors.lastname: Epifanova
authors.forename: A N
authors.initials: AN
authors.lastname: Rogoza
authors.forename: T V
authors.initials: TV
authors.lastname: Metelitsa
authors.forename: V B
authors.initials: VB
authors.lastname: Mychka
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D002908:Chronic Disease; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D017275:Isradipine / Q000008:administration & dosage*; D008297:Male; D013997:Time Factors
chemical_list: D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D017275:Isradipine